All In Biotech

Drug Trial Radar · NCT07160179

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Aug 13, 2025

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD. The purpose of this study is to assess the adverse events and how intravitreal ABBV-6628 moves through the body of adult participants with secondary to age-related macular degeneration ABBV-6628 is an investigational monoclonal antibody fragment being developed for the treatment of geographic atrophy (GA) secondary to (AMD) age-related macular degeneration. Participants in the Stage 1 part will be placed in 1 of 4 groups, called treatment arms. Participants in Stage 2 will be placed into 1 of 2 groups. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis GA secondary to age-related macular degeneration will be enrolled. Around 66 participants will be enrolled in the study at approximately 27 sites across the US. Participants in Stage 1 will be given ABBV-6628 as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection) with dose escalation. Participants in Stage 2 will receive ABBV-6628 or SYFOVRE, an approved treatment for geographic atrophy, administered as per the FDA-approved label. The treatment duration is approximately 22 months and 3 months of follow-up. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Geographic Atrophy
  • Age-Related Macular Degeneration

Interventions

  • ABBV-6628Drug

    Intravitreal injection

  • SYFOVREDrug

    Intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 25 months
  2. Number of Participants with Abnormal Change in Physical ExaminationsTime frame: Up to approximately 25 months
  3. Number of Participants with Abnormal Change From Baseline in Vital Sign MeasurementsTime frame: Up to approximately 25 months
  4. Change From Baseline in Electrocardiograms (ECGs)Time frame: Up to approximately 25 months
  5. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be AssessedTime frame: Up to approximately 25 months
  6. Change from baseline in Best Corrected Visual Acuity (BCVA)Time frame: Up to approximately 25 months
  7. Change in Slit lamp biomicroscopy assessmentTime frame: Up to approximately 25 months
  8. Change in Intraocular pressure (IOP)Time frame: Up to approximately 25 months
  9. Change in Lens examination assessmentTime frame: Up to approximately 25 months
  10. Change in Ophthalmoscopy assessmentTime frame: Up to approximately 25 months
  11. Change in fundus autofluorescence (FAF) imaging assessed by InvestigatorTime frame: Up to approximately 25 months
  12. Change in Retinal evaluationTime frame: Up to approximately 25 months
  13. Change in spectral domain optical coherence tomography (SD-OCT)Time frame: Up to approximately 25 months
  14. Change in Fluorescein angiography (FA) assessed by Investigator.Time frame: Up to approximately 25 months
  15. Change in choroidal neovascularization (CNV) assessed by Investigator.Time frame: Up to approximately 25 months
  16. Percentage of Participants with Clinically Significant Post-treatment Administration Assessment (study eye only) Findings as Assessed by the InvestigatorTime frame: Up to approximately 25 months
  17. Maximum Serum Concentration (Cmax) of ABBV-6628Time frame: Up to approximately 25 months
  18. Time to Cmax (Tmax) of ABBV-6628Time frame: Up to approximately 25 months
  19. Area Under the Concentration-Time Curve From zero to the last measurable Timepoint (AUC0-Tlast) of ABBV-6628Time frame: Up to approximately 25 months
  20. Stage 2-Trough serum concentration immediately before next dose (Ctrough) of ABBV-6628Time frame: Up to approximately 12 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Retina Partners Midwest, P.C. /ID# 262172

    Carmel, Indiana · Recruiting

  • Sierra Eye Associates /ID# 262142

    Reno, Nevada · Recruiting

  • Retina Research Institute of Texas /ID# 262141

    Abilene, Texas · Recruiting

  • Retina Foundation of the Southwest /ID# 262479

    Dallas, Texas · Recruiting

  • Retina Consultants - The Woodlands /ID# 262138

    The Woodlands, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.